Duchenne News Tags: Antisense Therapeutics

June 8, 2023
Antisense Therapeutics announces that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne.
May 23, 2023
Antisense announces approval to conduct phase 2b trial of ATL1102 and appoints CEO Dr. James Garner

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open